Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer

Clinical trial NCT03931551 · TERMINATED

Trial details

NCT number: NCT03931551
Sponsor: MedSIR
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Breast Cancer

Start date: 2019-04-30
Primary completion: 2022-03-02
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.